BRIEF published on 04/03/2025 at 13:18, 1 year 2 months ago Innate Pharma to Engage in Stifel 2025 Virtual Oncology Forum Biotechnology Immunotherapy Virtual Event Innate Pharma Oncology Forum 2025
BRIEF published on 04/03/2025 at 13:18, 1 year 2 months ago Innate Pharma participera au forum virtuel d'oncologie Stifel 2025 Biotechnologie Immunothérapie Événement Virtuel Innate Pharma Forum D'oncologie 2025
PRESS RELEASE published on 04/03/2025 at 13:13, 1 year 2 months ago INSIDE INFORMATION / OTHER NEWS RELEASES Innate Pharma to participate in 2025 Stifel Virtual Targeted Oncology Forum. Executive team presenting and hosting 1x1 meetings. Focus on innovative cancer immunotherapies Cancer Innate Pharma Immunothérapies Stifel Targeted Oncology Forum
PRESS RELEASE published on 03/28/2025 at 14:37, 1 year 2 months ago Annual financial and audit reports / Annual financial report
PRESS RELEASE published on 03/28/2025 at 14:32, 1 year 2 months ago Rapports financiers et d'audit annuels / Rapport financier annuel
BRIEF published on 03/20/2025 at 07:05, 1 year 3 months ago Innate Pharma annonce une conférence sur les résultats financiers 2024 Résultats Financiers Conférence Téléphonique Cotation Boursière Innate Pharma Immunothérapie Cancer
BRIEF published on 03/20/2025 at 07:05, 1 year 3 months ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 1 year 3 months ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2024. Détails de l'événement et informations pratiques disponibles sur www.innate-pharma.com Résultats Financiers Webcast Conférence Téléphonique Innate Pharma Biotechnologies
PRESS RELEASE published on 03/20/2025 at 07:00, 1 year 3 months ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 year 4 months ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
Published on 06/27/2026 at 01:40, 58 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 2 hours 38 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 3 hours 38 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 3 hours 48 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 4 hours 23 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 2 hours 32 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 2 hours 33 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 3 hours 2 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 3 hours 2 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 3 hours 10 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
